Education
About Us
Working with TipRanks
Follow Us
Plus Therapeutics (PSTV)
:PSTV
PSTV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.16 - $2.31
Previous CloseN/A
Volume69.06K
Average Volume (3M)47.73M
Market Cap
$39.80M
Enterprise Value$4.01M
Total Cash (Recent Filing)$9.87M
Total Debt (Recent Filing)$40.00K
Price to Earnings (P/E)―
Beta2.35
Next Earnings
Aug 18, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.19
Shares Outstanding60,490,100
10 Day Avg. Volume28,013,885
30 Day Avg. Volume47,726,188
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.10
Enterprise Value/Revenue1.72
Enterprise Value/Gross Profit-6.51
Enterprise Value/Ebitda-0.21
Forecast
1Y Price Target
$11.75Price Target Upside1680.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Clinical ProgressThe company is making solid progress in its drug development with key milestones expected for glioblastoma, leptomeningeal metastases, and pediatric brain cancer.
Diagnostic Platform LaunchThe upcoming launch of the CNSide platform, a novel diagnostic tool for leptomeningeal metastases, is expected to be a major positive for the stock.
Financial StabilityThe company has a solid balance sheet with $10 million in cash and no debt, and it raised $18 million in Q1, providing enough financial resources into 2026.
Bears Say
Earnings PerformanceThe company reported $1.0M in grant revenues in Q1, compared to consensus estimated revenue of $1.5M, and a net loss of $1.19 per share, compared to consensus estimated net loss of $0.25 per share.
Stock DilutionLowering the 12-month price target to $5.50 per share from $8.00 to account for the increased number of outstanding shares and warrants.
Plus Therapeutics News
PSTV FAQ
What was Plus Therapeutics’s price range in the past 12 months?
Plus Therapeutics lowest stock price was $0.16 and its highest was $2.31 in the past 12 months.
What is Plus Therapeutics’s market cap?
Plus Therapeutics’s market cap is $39.80M.
When is Plus Therapeutics’s upcoming earnings report date?
Plus Therapeutics’s upcoming earnings report date is Aug 18, 2025 which is in 10 days.
How were Plus Therapeutics’s earnings last quarter?
Plus Therapeutics released its earnings results on May 30, 2025. The company reported -$1.19 earnings per share for the quarter, missing the consensus estimate of -$0.248 by -$0.942.
Is Plus Therapeutics overvalued?
According to Wall Street analysts Plus Therapeutics’s price is currently Undervalued.
Does Plus Therapeutics pay dividends?
Plus Therapeutics does not currently pay dividends.
What is Plus Therapeutics’s EPS estimate?
Plus Therapeutics’s EPS estimate is -0.09.
How many shares outstanding does Plus Therapeutics have?
Plus Therapeutics has 60,490,100 shares outstanding.
What happened to Plus Therapeutics’s price movement after its last earnings report?
Plus Therapeutics reported an EPS of -$1.19 in its last earnings report, missing expectations of -$0.248. Following the earnings report the stock price went up 27.586%.
Which hedge fund is a major shareholder of Plus Therapeutics?
Currently, no hedge funds are holding shares in PSTV
Plus Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.75 (1680.30% Upside)
$11.75 (1680.30% Upside)
Blogger Sentiment
Bullish
PSTV Sentiment 70%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.0%
Last 30 Days ▲ 24.9%
Last 30 Days ▲ 24.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.56%
12-Months-Change
Fundamentals
Return on Equity
249.03%
Trailing 12-Months
Asset Growth
114.48%
Trailing 12-Months
Company Description
Plus Therapeutics
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative, targeted radiotherapeutics for patients with rare and difficult-to-treat cancers. The company operates primarily in the biotechnology and healthcare sectors, leveraging its proprietary nanotechnology platform to deliver precision radiotherapy. Plus Therapeutics is dedicated to improving the lives of cancer patients through the development of novel therapies aimed at enhancing treatment efficacy and minimizing side effects.
PSTV Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a mix of promising clinical trial results, successful financing, and strategic acquisitions that position Plus Therapeutics for future growth. However, these positives were offset by an increase in operating loss and a decline in cash reserves. The overall sentiment leans towards optimism due to strong forward-looking developments.View all PSTV earnings summariesPSTV Stock 12 Month Forecast
Average Price Target
$11.75
▲(1680.30% Upside)
Technical Analysis
Eterna Therapeutics
―
Minerva Neurosciences
―
Affimed
―
GeoVax Labs
―
Addex Therapeutics
―
Ownership Overview
10.15% Insiders
0.15% Mutual Funds
0.11% Other Institutional Investors
89.54% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---